Akston Biosciences was founded by the former team of SmartCells that, having developed the worlds first clinical glucose responsive insulin, was acquired by Merck & Co. for over $500M. Combining the Akston management team's core expertise with modern biotechnology manufacturing techniques, Akston is now working on medical insulin devices intended to prevent diabetes. The firm is structured around developing new classes of biologic therapeutics for use in autoimmune Type 1 diabetes prevention, ultra-long acting insulin therapy, and oncology to dramatically improve both human and animal health. The company's devices can be used in autoimmune Type 1 diabetes prevention, ultra-long-acting insulin therapy and oncology over 24 hours of hypoglycemia-free glucose control in diabetic mice with a single injection, enabling doctors to improve glucose control, reduce complications and eliminate hypoglycemia risk for human and animal health.
